OTLK

$0.00

(

+0.00%

)
Quote details

stock

OUTLOOK THERAPEUTICS INC

NASDAQ | OTLK

1.19

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 7, 2025)

$52.42M

Market Cap

-

P/E Ratio

-0.84

EPS

$6.61

52 Week High

$0.79

52 Week Low

HEALTHCARE

Sector

OTLK Chart

Recent Chart
Price Action

OTLK Technicals

Tags:

OTLK Earnings

Yearly Income Statement (As of Sep 30, 2024)

Field Value (USD)
Gross Profit -$114K
Total Revenue $170K
Cost Of Revenue $114K
Costof Goods And Services Sold $114K
Operating Income -$72M
Selling General And Administrative $30M
Research And Development $42M
Operating Expenses $72M
Investment Income Net -
Net Interest Income -$2.3M
Interest Income $906K
Interest Expense $3.2M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $114K
Income Before Tax -$75M
Income Tax Expense $2.8K
Interest And Debt Expense -
Net Income From Continuing Operations -$75M
Comprehensive Income Net Of Tax -
Ebit -$72M
Ebitda -$72M
Net Income -$75M

Revenue & Profitability

Earnings Performance

OTLK Financials

yearly Balance Sheet (As of Sep 30, 2024)

Field Value (USD)
Total Assets $29M
Total Current Assets $27M
Cash And Cash Equivalents At Carrying Value $15M
Cash And Short Term Investments $15M
Inventory -
Current Net Receivables -
Total Non Current Assets $1.4M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $693K
Short Term Investments $15T
Other Current Assets $12M
Other Non Current Assets -
Total Liabilities $102M
Total Current Liabilities $43M
Current Accounts Payable $8M
Deferred Revenue -
Current Debt -
Short Term Debt $29M
Total Non Current Liabilities $59M
Capital Lease Obligations $298K
Long Term Debt -
Current Long Term Debt $29M
Long Term Debt Noncurrent -
Short Long Term Debt Total $30M
Other Current Liabilities $3.2M
Other Non Current Liabilities -
Total Shareholder Equity -$73M
Treasury Stock -
Retained Earnings -$543M
Common Stock $239K
Common Stock Shares Outstanding $19M

yearly Cash Flow (As of Sep 30, 2024)

Field Value (USD)
Operating Cashflow -$69M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $114K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $60M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$75M

yearly Income Statement (As of Sep 30, 2024)

Field Value (USD)
Gross Profit -$114K
Total Revenue $170K
Cost Of Revenue $114K
Costof Goods And Services Sold $114K
Operating Income -$72M
Selling General And Administrative $30M
Research And Development $42M
Operating Expenses $72M
Investment Income Net -
Net Interest Income -$2.3M
Interest Income $906K
Interest Expense $3.2M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $114K
Income Before Tax -$75M
Income Tax Expense $2.8K
Interest And Debt Expense -
Net Income From Continuing Operations -$75M
Comprehensive Income Net Of Tax -
Ebit -$72M
Ebitda -$72M
Net Income -$75M

OTLK News

OTLK Profile

OUTLOOK THERAPEUTICS INC Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Outlook Therapeutics, Inc. is a late-stage biopharmaceutical firm based in Cranbury, New Jersey, dedicated to the development of pioneering monoclonal antibody therapies aimed at treating ocular diseases. The company focuses on addressing significant unmet medical needs within the ophthalmology field, with a robust pipeline targeting critical retinal conditions. As it advances towards regulatory approvals and potential commercialization, Outlook Therapeutics is well-positioned to enhance patient care and clinical outcomes in vision health, leveraging its specialized expertise to improve the quality of life for those affected by serious eye diseases.

BKYI
+51.56%
$0.96
RUBI
+39.37%
$0.31
AZI
-4.05%
$0.09
NVDA
+0.03%
$188.15
ASST
+4.13%
$1.51
ACHR
-7.88%
$8.18
BYND
+16.80%
$1.39
PFE
+0.04%
$24.43
PLUG
+5.57%
$2.65
ONDS
+10.66%
$5.81
MSGM
+70.77%
$3.74
TSLA
-3.67%
$429.52
INTC
+2.38%
$38.13
VHAI
0.00%
$0.00
GRAB
-1.24%
$5.56
F
+1.82%
$13.21
SOFI
+3.86%
$28.21
DNN
-0.39%
$2.54
PLTR
+1.64%
$177.93
WTO
-7.52%
$0.04
BITF
-0.81%
$3.66
SNAP
+2.49%
$8.21
AAL
+3.80%
$13.65
AXDX
-61.36%
$0.03
NIO
-4.18%
$6.86
RIVN
+0.06%
$15.23
CHR
+0.15%
$0.06
DVLT
+24.26%
$1.69
T
+0.36%
$24.83
ETHD
-9.69%
$4.38
RGTI
-1.71%
$33.77
BURU
+3.54%
$0.28
BTG
+2.89%
$3.91
PBR
+5.93%
$12.86
IREN
-6.83%
$62.38
JOBY
+4.05%
$14.90
RXRX
0.00%
$4.62
PRMB
-18.30%
$14.46
AMD
-1.75%
$233.54
MARA
-0.56%
$15.87
ADAP
-15.14%
$0.05
QBTS
+3.90%
$29.50
SOUN
-0.63%
$14.14
IONZ
-6.57%
$3.55
YDKG
-1.56%
$0.05
NVTS
-11.26%
$7.84
AAPL
-0.48%
$268.47
KVUE
+2.55%
$16.88
AMZN
+0.56%
$244.41
BMNR
+7.65%
$40.22
CIFR
-4.69%
$20.69
HOOD
+2.58%
$130.36
MTVA
+6.84%
$0.90
WULF
-2.38%
$13.94
SMR
-6.53%
$30.34
BTBT
+3.63%
$3.14
DKNG
+8.64%
$30.40
EOSE
+19.42%
$18.26
NOK
-1.01%
$6.84
BAC
-0.16%
$53.20
RMBL
+60.50%
$3.21
ABEV
+1.25%
$2.43
RIG
+2.05%
$3.98
ADD
-25.47%
$0.05
TLRY
+2.47%
$1.24
VIVK
+11.85%
$0.16
GPUS
+0.43%
$0.37
SRM
+53.27%
$10.30
GOOGL
-2.07%
$278.83
TTD
-6.31%
$43.00
CMG
+0.09%
$30.59
QS
+4.52%
$16.62
ORGO
+44.73%
$5.63
SMCI
-1.42%
$39.76
IONQ
+3.20%
$59.27
PLTZ
-3.51%
$6.86
FIG
-3.76%
$44.25
EPWK
+3.23%
$0.07
VALE
-0.65%
$12.15
WBD
+1.11%
$22.67
MU
-0.17%
$237.92
AMC
-7.30%
$2.41
RF
+2.22%
$24.85
META
+0.44%
$621.71
MTC
-6.85%
$2.58
PTON
+14.15%
$7.66
ELDN
-49.75%
$2.06
IOVA
-0.43%
$2.29
CGC
+7.33%
$1.17
HIMS
-1.18%
$41.03
WLGS
-5.57%
$0.04
CAN
+5.30%
$1.19
VZ
+0.52%
$40.03
BBD
+0.85%
$3.54
HBAN
+1.75%
$15.69
QUBT
-2.20%
$12.86
NGD
+1.58%
$7.03
CLSK
+1.10%
$15.57
ETWO
0.00%
$3.30
AMCR
+1.82%
$8.36
BKYI
+51.56%
$0.96
RUBI
+39.37%
$0.31
AZI
-4.05%
$0.09
NVDA
+0.03%
$188.15
ASST
+4.13%
$1.51
ACHR
-7.88%
$8.18
BYND
+16.80%
$1.39
PFE
+0.04%
$24.43
PLUG
+5.57%
$2.65
ONDS
+10.66%
$5.81
MSGM
+70.77%
$3.74
TSLA
-3.67%
$429.52
INTC
+2.38%
$38.13
VHAI
0.00%
$0.00
GRAB
-1.24%
$5.56
F
+1.82%
$13.21
SOFI
+3.86%
$28.21
DNN
-0.39%
$2.54
PLTR
+1.64%
$177.93
WTO
-7.52%
$0.04
BITF
-0.81%
$3.66
SNAP
+2.49%
$8.21
AAL
+3.80%
$13.65
AXDX
-61.36%
$0.03
NIO
-4.18%
$6.86
RIVN
+0.06%
$15.23
CHR
+0.15%
$0.06
DVLT
+24.26%
$1.69
T
+0.36%
$24.83
ETHD
-9.69%
$4.38
RGTI
-1.71%
$33.77
BURU
+3.54%
$0.28
BTG
+2.89%
$3.91
PBR
+5.93%
$12.86
IREN
-6.83%
$62.38
JOBY
+4.05%
$14.90
RXRX
0.00%
$4.62
PRMB
-18.30%
$14.46
AMD
-1.75%
$233.54
MARA
-0.56%
$15.87
ADAP
-15.14%
$0.05
QBTS
+3.90%
$29.50
SOUN
-0.63%
$14.14
IONZ
-6.57%
$3.55
YDKG
-1.56%
$0.05
NVTS
-11.26%
$7.84
AAPL
-0.48%
$268.47
KVUE
+2.55%
$16.88
AMZN
+0.56%
$244.41
BMNR
+7.65%
$40.22
CIFR
-4.69%
$20.69
HOOD
+2.58%
$130.36
MTVA
+6.84%
$0.90
WULF
-2.38%
$13.94
SMR
-6.53%
$30.34
BTBT
+3.63%
$3.14
DKNG
+8.64%
$30.40
EOSE
+19.42%
$18.26
NOK
-1.01%
$6.84
BAC
-0.16%
$53.20
RMBL
+60.50%
$3.21
ABEV
+1.25%
$2.43
RIG
+2.05%
$3.98
ADD
-25.47%
$0.05
TLRY
+2.47%
$1.24
VIVK
+11.85%
$0.16
GPUS
+0.43%
$0.37
SRM
+53.27%
$10.30
GOOGL
-2.07%
$278.83
TTD
-6.31%
$43.00
CMG
+0.09%
$30.59
QS
+4.52%
$16.62
ORGO
+44.73%
$5.63
SMCI
-1.42%
$39.76
IONQ
+3.20%
$59.27
PLTZ
-3.51%
$6.86
FIG
-3.76%
$44.25
EPWK
+3.23%
$0.07
VALE
-0.65%
$12.15
WBD
+1.11%
$22.67
MU
-0.17%
$237.92
AMC
-7.30%
$2.41
RF
+2.22%
$24.85
META
+0.44%
$621.71
MTC
-6.85%
$2.58
PTON
+14.15%
$7.66
ELDN
-49.75%
$2.06
IOVA
-0.43%
$2.29
CGC
+7.33%
$1.17
HIMS
-1.18%
$41.03
WLGS
-5.57%
$0.04
CAN
+5.30%
$1.19
VZ
+0.52%
$40.03
BBD
+0.85%
$3.54
HBAN
+1.75%
$15.69
QUBT
-2.20%
$12.86
NGD
+1.58%
$7.03
CLSK
+1.10%
$15.57
ETWO
0.00%
$3.30
AMCR
+1.82%
$8.36

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.